検索リコンビナントタンパク質
ACROBiosystems社 プロダクトリスト：Recombinant Protein
- サプライヤー
- AcroBioSystems
- カタログNo.
- HL1-H82E3
- 製品名称
- Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein (Monomer, MALS verified)
- タンパク質名
- HLA-A*2402 & B2M & NY-ESO-1 (LLMWITQCF)
- Species
- Human
- HOST
- HEK293
Overview
| Synonyms | - |
|---|---|
| Characteristics | Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?). The protein has a calculated MW of 35.8 kDa and 11.7 kDa. The protein migrates as 38-42 kDa and <14 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation. |
| Endotoxin Level | 1.0 EU per μg |
| Purity | 90% |
| Description | NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A24 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*2402 NY-ESO-1 (LLMWITQCF) complex protein is a complex of HLA-A*2402 of the MHC Class I, B2M and LLMWITQCF peptide of the NY-ESO-1. |
| Reference | - |
| URL | https://www.acrobiosystems.com/P6469-Biotinylated-Human-HLA-A%2A24%3A02B2MNY-ESO-1-%28LLMWITQCF%29-Complex-Protein-%28Monomer-MALS-verified%29.html |
お問い合わせリスト